TY  - JOUR
A1  - Schön, Michael P.
A1  - Berking, Carola
A1  - Biedermann, Tilo
A1  - Buhl, Timo
A1  - Erpenbeck, Luise
A1  - Eyerich, Kilian
A1  - Eyerich, Stefanie
A1  - Ghoreschi, Kamran
A1  - Goebeler, Matthias
A1  - Ludwig, Ralf J.
A1  - Schäkel, Knut
A1  - Schilling, Bastian
A1  - Schlapbach, Christoph
A1  - Stary, Georg
A1  - von Stebut, Esther
A1  - Steinbrink, Kerstin
T1  - COVID‐19 and immunological regulations – from basic and translational aspects to clinical implications
JF  - JDDG: Journal der Deutschen Dermatologischen Gesellschaft
N2  - The COVID‐19 pandemic caused by SARS‐CoV‐2 has far‐reaching direct and indirect medical consequences. These include both the course and treatment of diseases. It is becoming increasingly clear that infections with SARS‐CoV‐2 can cause considerable immunological alterations, which particularly also affect pathogenetically and/or therapeutically relevant factors.
Against this background we summarize here the current state of knowledge on the interaction of SARS‐CoV‐2/COVID‐19 with mediators of the acute phase of inflammation (TNF, IL‐1, IL‐6), type 1 and type 17 immune responses (IL‐12, IL‐23, IL‐17, IL‐36), type 2 immune reactions (IL‐4, IL‐13, IL‐5, IL‐31, IgE), B‐cell immunity, checkpoint regulators (PD‐1, PD‐L1, CTLA4), and orally druggable signaling pathways (JAK, PDE4, calcineurin). In addition, we discuss in this context non‐specific immune modulation by glucocorticosteroids, methotrexate, antimalarial drugs, azathioprine, dapsone, mycophenolate mofetil and fumaric acid esters, as well as neutrophil granulocyte‐mediated innate immune mechanisms.
From these recent findings we derive possible implications for the therapeutic modulation of said immunological mechanisms in connection with SARS‐CoV‐2/COVID‐19. Although, of course, the greatest care should be taken with patients with immunologically mediated diseases or immunomodulating therapies, it appears that many treatments can also be carried out during the COVID‐19 pandemic; some even appear to alleviate COVID‐19.
KW  - COVID-19
KW  - SARS-CoV-2
KW  - immunology
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-218205
VL  - 18
IS  - 8
SP  - 795
EP  - 807
ER  - 
TY  - JOUR
A1  - Schatton, Tobias
A1  - Yang, Jun
A1  - Kleffel, Sonja
A1  - Uehara, Mayuko
A1  - Barthel, Steven R.
A1  - Schlapbach, Christoph
A1  - Zhan, Qian
A1  - Dudeney, Stephen
A1  - Mueller, Hansgeorg
A1  - Lee, Nayoung
A1  - de Vries, Juliane C.
A1  - Meier, Barbara
A1  - Beken, Seppe Vander
A1  - Kluth, Mark A.
A1  - Ganss, Christoph
A1  - Sharpe, Arlene H.
A1  - Waaga-Gasser, Ana Maria
A1  - Sayegh, Mohamed H.
A1  - Abdi, Reza
A1  - Scharffetter-Kochanek, Karin
A1  - Murphy, George F.
A1  - Kupper, Thomas S.
A1  - Frank, Natasha Y.
A1  - Frank, Markus H.
T1  - ABCB5 Identifies Immunoregulatory Dermal Cells
JF  - Cell Reports
N2  - Cell-based strategies represent a new frontier in the treatment of immune-mediated disorders. However, the paucity of markers for isolation of molecularly defined immunomodulatory cell populations poses a barrier to this field. Here, we show that ATP-binding cassette member B5 (ABCB5) identifies dermal immunoregulatory cells (DIRCs) capable of exerting therapeutic immunoregulatory functions through engagement of programmed cell death 1 (PD-1). Purified Abcb5\(^+\) DIRCs suppressed T cell proliferation, evaded immune rejection, homed to recipient immune tissues, and induced Tregs in vivo. In fully major-histocompatibility-complex-mismatched cardiac allotransplantation models, allogeneic DIRCs significantly prolonged allograft survival. Blockade of DIRC-expressed PD-1 reversed the inhibitory effects of DIRCs on T cell activation, inhibited DIRC-dependent Treg induction, and attenuated DIRC-induced prolongation of cardiac allograft survival, indicating that DIRC immunoregulatory function is mediated, at least in part, through PD-1. Our results identify ABCB5\(^+\) DIRCs as a distinct immunoregulatory cell population and suggest promising roles of this expandable cell subset in cellular immunotherapy.
KW  - mesenchymal stem cells
KW  - P-glycoprotein
KW  - regulatory T cells
KW  - maintain immune homeostasis
KW  - malignant melanoma
KW  - in vivo
KW  - skin
KW  - generation
KW  - transplant
KW  - tolerance
Y1  - 2015
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-149989
VL  - 12
SP  - 1564
EP  - 1574
ER  -